Dan Galles

Gauss is the leader in computer vision in healthcare. Founded in 2011, Gauss’s mission is to digitally augment clinicians with software that radically improves diagnostic accuracy and leads to improved patient safety and clinical outcomes. Gauss’s flagship product, Triton, leverages computer vision to detect surgical and obstetric hemorrhage in real time and notifies clinicians who can enact timely intervention and treatment. Triton was granted De Novo clearance from the U.S. Food and Drug Administration (FDA) in 2014, as the first-ever computer vision software for surgical use, and several follow-on 510(k) clearances. Available on the iPhone, Triton has been widely adopted by health systems in the United States and is a recipient of the Apple Design Award, which recognizes the best in design, innovation and technology on Apple platforms. Gauss was acquired by Stryker (NYSE: SYK) in 2021. For more information, visit http://www.gauss.com.

Gauss is the leader in computer vision in healthcare. Founded in 2011, Gauss’s mission is to digitally augment clinicians with software that radically improves diagnostic accuracy and leads to improved patient safety and clinical outcomes. Gauss’s flagship product, Triton, leverages computer vision to detect surgical and obstetric hemorrhage in real time and notifies clinicians who can enact timely intervention and treatment. Triton was granted De Novo clearance from the U.S. Food and Drug Administration (FDA) in 2014, as the first-ever computer vision software for surgical use, and several follow-on 510(k) clearances. Available on the iPhone, Triton has been widely adopted by health systems in the United States and is a recipient of the Apple Design Award, which recognizes the best in design, innovation and technology on Apple platforms. Gauss was acquired by Stryker (NYSE: SYK) in 2021. For more information, visit http://www.gauss.com.

Founded in 2014, Providence Ventures ("PV") is a venture capital firm focused on Digital Health, Tech-enabled Healthcare Services, and MedTech. We target venture-class returns through direct investments in innovative healthcare companies that effectively address the top pain points of the healthcare ecosystem. We partner with entrepreneurs largely as representatives of enterprise health systems, offering customer-level insight and access to decision-makers of some of the largest customers in the market. Of note, our LP is the Providence health system, among the largest health systems in the United States. We leverage our relationship with Providence to drive adoption within and beyond our LP.